Gene

PROM1

prominin 1

Explore in graph →CI-GENE-00021068HGNC:9454 ENSG00000007062 NCBI 8842 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PROM1 EXPRESSION1
Sorafenib	Hepatocellular Carcinoma	Predictive	B	Supports Resistance	2	accepted	EID926 CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) wer… (full text at CIViC) PMID 22596232 · Hagiwara et al., 2012 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Chronic lymphocytic leukemia (ICGC, Nature Genetics 2011) cllsll_icgc_2011	Small Lymphocytic Lymphoma	Ssm	2

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed